The estimated Net Worth of John Frederick Ek is at least $8.06 million dollars as of 21 January 2021. Mr. Ek owns over 50,449 units of GenMark Diagnostics Inc stock worth over $5,498,741 and over the last 6 years he sold GNMK stock worth over $1,435,845. In addition, he makes $1,129,380 as Chief Financial Officer at GenMark Diagnostics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Ek GNMK stock SEC Form 4 insiders trading
Johnny has made over 24 trades of the GenMark Diagnostics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 50,449 units of GNMK stock worth $1,212,794 on 21 January 2021.
The largest trade he's ever made was exercising 50,449 units of GenMark Diagnostics Inc stock on 21 January 2021 worth over $1,212,794. On average, Johnny trades about 5,900 units every 24 days since 2019. As of 21 January 2021 he still owns at least 228,733 units of GenMark Diagnostics Inc stock.
You can see the complete history of Mr. Ek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Johnny Ek biography
Johnny Ek serves as Chief Financial Officer of the Company. Prior to serving as the Company’s Chief Financial Officer, Mr. Ek served as the Company’s Vice President, Finance and Accounting and Corporate Controller from November 2013 to February 2019. Prior to joining the Company, Mr. Ek served as Vice President and International Controller for Affymetrix, Inc., a leading provider of cellular and genetic analysis products, from May 2013 to November 2013. Prior to joining Affymetrix, Mr. Ek served as Controller of eBioscience, Inc., a privately held provider of flow cytometry and immunoassay reagents, from October 2010 through eBioscience’s acquisition by Affymetrix in May 2013. Prior to joining eBioscience, Mr. Ek held various roles with Ernst & Young LLP from May 2001 to October 2010, most recently serving as Senior Manager. Mr. Ek is a Certified Public Accountant (CPA) and earned a B.S. in finance from Brigham Young University and a Masters degree in accountancy (MAcc) from the University of Notre Dame’s Mendoza College of Business.
What is the salary of Johnny Ek?
As the Chief Financial Officer of GenMark Diagnostics Inc, the total compensation of Johnny Ek at GenMark Diagnostics Inc is $1,129,380. There are 1 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.
How old is Johnny Ek?
Johnny Ek is 43, he's been the Chief Financial Officer of GenMark Diagnostics Inc since 2019. There are 9 older and no younger executives at GenMark Diagnostics Inc. The oldest executive at GenMark Diagnostics Inc is Daryl Faulkner, 71, who is the Independent Director.
Insiders trading at GenMark Diagnostics Inc
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem et Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
What does GenMark Diagnostics Inc's logo look like?
Complete history of Mr. Ek stock trades at GenMark Diagnostics Inc
GenMark Diagnostics Inc executives and stock owners
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Scott Mendel,
President, Chief Executive Officer, Director -
Johnny Ek,
Chief Financial Officer -
Michael Gleeson,
Senior Vice President, Corporate Accounts -
Eric Stier,
Senior Vice President, General Counsel, Secretary -
James Fox,
Non-Executive Independent Director -
Kevin O'Boyle,
Independent Chairman of the Board -
Lisa Giles,
Independent Director -
Daryl Faulkner,
Independent Director -
Michael Kagnoff,
Independent Director -
Tyler Jensen,
Senior Vice President - Engineering and Product Technical Support -
Jon Faiz Kayyem,
President & CEO -
Jennifer Anne Williams,
SVP Global Operations -
Wade R. Stevenson,
SVP, North America Sales -
Brian Andrew Mitchell,
SVP, Operations -
Christine Shaw,
VP, Assay Development -
John Frederick Ek,
Chief Financial Officer -
Richard B Slansky,
Chief Financial Officer -
Stephen T Worland,
Director -
Jeffrey Alan Hawkins,
SVP, Marketing & Bus Dev -
Ingo Chakravarty,
SVP, International -
Christopher M Gleeson,
Director -
James B. Mc Nally,
SVP, Marketing and Bus. Dev. -
Jorge Garces,
SVP, Research & Development -
Paul Ross,
CFO & Secretary -
Pankaj Singhal,
Sr. VP, Product Dev & Mftg -
Matthew Robert Cohen,
SVP, Gen Counsel & Secretary -
John Bellano,
SR. VP, Commercial Operations -
Steven J Kemper,
CFO, Treasurer & Secretary -
Bradley Calvin,
Senior VP, Global Marketing -
Scott Alexander O'brien,
SVP, Global Mktg & Int'l Sales -
Hany Massarany,
President and CEO -
Sarah Hollis Winkler,
VP, Human Resources -
Alan Baer Maderazo,
VP, Qual, Reg, & Clin Affairs -
Michael John Harkins,
SVP, Sales -
Abdul Chohan,
SVP Operations